San Diego – November 20, 2024 – Cooley advised clinical-stage biopharmaceutical company Kura Oncology (Nasdaq: KURA) on its global strategic collaboration with Kyowa Kirin to develop and commercialize ziftomenib, Kura’s selective oral menin inhibitor that is being investigated for the treatment of acute myeloid leukemia (AML) and other hematologic malignancies. Under the terms of the agreement, Kura, which is committed to realizing the promise of precision medicines for cancer treatment, will receive an upfront payment of $330 million and expects to receive up to $420 million in near-term milestone payments, including a payment upon the launch of ziftomenib in the monotherapy relapsed/refractory setting for patients with AML. In addition, Kura is eligible to receive additional development, regulatory and commercial milestone payments of $741 million, totaling up to $1.161 billion in payments for milestones and the opt-in for solid tumor indications.
The Cooley team advising Kura is led by life sciences partner Charity Williams and associates Chen Chen and Jonathan Kaufman; tax partners Aaron Pomeroy and Todd Gluth and associate Amanda Pacheco; antitrust partner Howard Morse and special counsel David Burns; corporate partner Charles Bair; and cyber/data/privacy special counsel Andrew Epstein.
Cooley has represented Kura Oncology since its inception in 2014, guiding the company through its initial funding, initial public offering and follow-on offerings, including its oversubscribed $150 million private placement in January 2024.
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 1,300+ lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.